Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Chief Scientific Officer | December 09, 2021 | December 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Foghorn Therapeutics Inc.
Report date December 09, 2021 · Filed December 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 362,707 |
Reported balance
After 2021-12-09 transaction · row 1
1 source rowRow 1 · 2021-12-09 · Exercise / conversion · Acquired 104,310 · Balance 362,707 |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2029-02-20 | Direct | 186,571 |
Reported balance
After 2021-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-09 · Exercise / conversion · Disposed 76,892 · Balance 186,571 F1: The option vested as to 25% of the underlying shares of common stock on December 10, 2019, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2029-02-20 | Direct | 34,273 |
Reported balance
After 2021-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-09 · Exercise / conversion · Disposed 27,418 · Balance 34,273 F2: The option vested as to 25% of the underlying shares of common stock on January 30, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested as to 25% of the underlying shares of common stock on December 10, 2019, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.
F2: The option vested as to 25% of the underlying shares of common stock on January 30, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2021 Filed Dec 14, 2021 01:37 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionStock Options (Right to buy) · Derivative | 27,418 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-007666 · primarydocument.xml · derivative · entry 3 DECICCO CARL · CIK 0001828727 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,273 Underlying: Common Stock · 27,418 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on January 30, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 01:37 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionStock Options (Right to buy) · Derivative | 76,892 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-007666 · primarydocument.xml · derivative · entry 2 DECICCO CARL · CIK 0001828727 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,571 Underlying: Common Stock · 76,892 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 10, 2019, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 01:37 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionCommon Stock | 104,310 | $3.72 | $388,033.20 |
DisclosureSEC source: 0001562180-21-007666 · primarydocument.xml · nonDerivative · entry 1 DECICCO CARL · CIK 0001828727 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 02:31 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0000899243-21-003977 · doc4.xml · derivative · entry 1 DECICCO CARL · CIK 0001828727 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The options will vest as to 25% of the underlying shares of common stock on January 28, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 21:01 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | PurchaseCommon Stock | 5,500 | $16.00 | $88,000.00 |
DisclosureSEC source: 0000899243-20-029696 · doc4.xml · nonDerivative · entry 1 DECICCO CARL · CIK 0001828727 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,397 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.